2. Academic Validation
  3. Inhibition of interleukin-1 receptor-associated kinase 1 (IRAK1) as a therapeutic strategy

Inhibition of interleukin-1 receptor-associated kinase 1 (IRAK1) as a therapeutic strategy

  • Oncotarget. 2018 Sep 7;9(70):33416-33439. doi: 10.18632/oncotarget.26058.
Jack W Singer 1,  Angela Fleischman 2,  Suliman Al-Fayoumi 1,  John O Mascarenhas 3,  Qiang Yu 4,  Anupriya Agarwal 5
Affiliations

Affiliations

  • 1 CTI Biopharma Corporation, Seattle, WA, USA.
  • 2 Chao Family Comprehensive Cancer Center, University of California Irvine, Irvine, CA, USA.
  • 3 Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • 4 Genome Institute of Singapore, Singapore, SG, Singapore.
  • 5 Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
PMID: 30279971 DOI: 10.18632/oncotarget.26058
Abstract

Interleukin-1 receptor-associated kinases (IRAK1, IRAK2, IRAK3 [IRAK-M], and IRAK4) are serine-threonine kinases involved in Toll-like Receptor and interleukin-1 signaling pathways, through which they regulate innate immunity and inflammation. Evidence exists that IRAKs play key roles in the pathophysiologies of cancers, and metabolic and inflammatory diseases, and that IRAK inhibition has potential therapeutic benefits. Molecules capable of selectively interfering with IRAK function and expression have been reported, paving the way for the clinical evaluation of IRAK inhibition. Herein, we focus on IRAK1, review its structure and physiological roles, and summarize emerging data for IRAK1 inhibitors in preclinical and clinical studies.

Keywords

MyD88; cancer; inflammatory diseases; interleukin-1 receptor associated kinase (IRAK1); pacritinib.

Figures